


It is believed that no fee is due for the submission of this Preliminary Amendment. If any fees are deemed to be due, the Assistant Commissioner is hereby authorized to charge said fee to Deposit Account No. 50-0552.

An early and favorable decision is earnestly solicited.

Respectfully Submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: \_\_\_\_\_

  
Robert J. Paradiso  
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
Tel. (212) 736-1940

**MARKED-UP VERSION TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

Please amend the specification as follows:

At page 1, please amend the title of the invention as follows:

-- ANALGESIC COMBINATION OF OXYCODONE AND [6-MNA] 6-METHOXY-2-NAPHTHYLACETIC ACID.--

At page 13, please amend the paragraph beginning at line 25 as follows:

- - Certain preferred COX-2 inhibitors include celecoxib (SC-58635), [DUP-697] 5-bromo-s-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl] thiophene (DUP-697), flosulide (CGP-28238), meloxicam, 6-methoxy-2 naphthylacetic acid (6-MNA), Vioxx (MK-966), nabumetone (prodrug for 6-MNA), nimesulide, [NS-398] N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398), [SC-5766] 1-fluoro-4-[2-[4-methylsulfonyl]phenyl]-1-cyclopenten-1-yl] benzene (SC-5766), [SC-58215] 5-(4-fluorophenyl)-1[4-(methylsulfonyl)phenyl]-3-trifluoromethyl 1H-pyrazole (SC-58215), [T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide (T-614); or combinations thereof. --

**IN THE CLAIMS**

30. (Amended) A pharmaceutical composition comprising an analgesic combination consisting essentially of [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.

31. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof would be subtherapeutic if administered without the [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof.

32. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof; and [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof are administered orally, via implant, parenterally, sublingually, rectally, topically, or via inhalation.

35. (Amended) The pharmaceutical composition according to claim 30, wherein the [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof synergistically potentiates the effect of the oxycodone and/or at least one pharmaceutically acceptable salt thereof but the oxycodone and/or at least one pharmaceutically acceptable salt thereof does not synergistically potentiate the effect of the [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof.

36. (Amended) The pharmaceutical composition according to claim 34, wherein the oral solid dosage form includes a sustained release carrier which causes the sustained release of the [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof; [.] the oxycodone and/or at least one pharmaceutically acceptable salt thereof; [.] or both the oxycodone and/or at least one pharmaceutically acceptable salt thereof and the [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof when the dosage form contacts gastrointestinal fluid.

37. (Amended) A method of effectively treating pain in humans or other mammals, comprising administering to a patient an analgesic combination consisting essentially of **[6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof**; and oxycodone **and/or at least one pharmaceutically acceptable salt thereof** such that the dosing interval of the **[6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof** overlaps with the dosing interval of the oxycodone **and/or at least one pharmaceutically acceptable salt thereof**.

38. (Amended) The method of claim 37, wherein the **[6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof** and the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** are administered orally.

39. (Amended) The method of claim 37, wherein the **[6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof** and the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** are administered in a single oral dosage form.

40. (Amended) The method of claim 37, wherein the oxycodone would be sub-therapeutic if administered without the **[6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof**.

41. (Amended) The method of claim 37, wherein the [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof is administered before, simultaneously with, or after administration of the oxycodone and/or at least one pharmaceutically acceptable salt thereof, such that the dosing interval of the [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

42. (Amended) A method of reducing the oxycodone and/or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain, comprising co-administering [said] oxycodone and/or at least one pharmaceutically acceptable salt thereof with said [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said oxycodone and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said oxycodone and/or at least one pharmaceutically acceptable salt thereof.

43. (Amended) A method of reducing the amount of [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salts thereof required to treat a patient affected with pain comprising co-administering said [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof with an effective amount of oxycodone and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof, during at least a portion of the dosage interval of said [6-MNA] 6-methoxy-2-naphthylacetic acid and/or at least one pharmaceutically acceptable salt thereof.

44. (Amended) The pharmaceutical composition according to claim [1] 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.

45. (Amended) The method of claim 37, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.